Unlike other glucagon-like peptide-1 (GLP-1) receptor agonists, BYDUREON BCise has a unique, continuous-release microsphere delivery system designed to provide consistent therapeutic levels of the ...
WILMINGTON, Del., Jan. 10, 2018 /PRNewswire/ -- AstraZeneca today announced that BYDUREON ® BCise™ (exenatide extended-release) injectable suspension 2mg is now available in pharmacies across the ...
Exenatide ext-rel 2mg; susp for SC inj; contains sucrose. Exenatide activates the GLP-1 receptor, thereby increasing intracellular cyclic AMP (cAMP) in beta cells leading to glucose-dependent insulin ...
AstraZeneca PLC AZN announced that the European Commission has granted approval to Bydureon BCise (exenatide extended-release) injectable suspension, a new formulation of its GLP-1 receptor agonist ...
AstraZeneca PLC AZN announced that the European Commission has granted approval to Bydureon BCise (exenatide extended-release) injectable suspension, a new formulation of its GLP-1 receptor agonist ...
Against the backdrop of challenges for its Type 2 diabetes Bydureon business, AstraZeneca has received some good news from the FDA. The U.S. regulatory agency green lit the therapy in children, making ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback